This legislation mandates that the Secretary of State , in collaboration with the Secretary of Health and Human Services and other relevant agencies, develop a comprehensive strategy within 18 months of enactment. The primary goal of this strategy is to secure international support from foreign countries, multilateral organizations, and other entities to accelerate the development and commercialization of qualified pandemic or epidemic products . A significant focus is placed on products designed to combat antimicrobial-resistant pathogens that pose a pandemic threat or are identified as priority pathogens. The strategy must outline processes for entering into international arrangements, ensuring equitable contributions based on participating entities' budgets and technical expertise. It aims to strengthen partner countries' public health capabilities, harmonize efforts to avoid duplication, and allocate joint or individual responsibilities for product development. Furthermore, the strategy should consider various mechanisms for commercialization, including contracts with U.S. companies, public-private partnerships, alternative payment models, and streamlined regulatory approvals. This initiative is intended to be synchronized with existing U.S. pandemic preparedness priorities, such as the National Strategy for Combating Antibiotic-Resistant Bacteria and the National Biodefense Strategy.